Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Biotin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Biotin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

A water-soluble, enzyme co-factor present in minute amounts in every living cell.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (649 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Vitamin H; Biodermatin; Biokur; Biotin Gelfert; Gelfert, Biotin; Biotin Hermes; Hermes, Biotin; Deacura.

Where it fits in the MeSH classification

Broader topics
Imidazoles; Coenzymes
See also
Avidin; Multiple Carboxylase Deficiency; Biotinidase Deficiency; Holocarboxylase Synthetase Deficiency

Research landscape

PubMed indexes 15,491 records tagged with the MeSH heading “Biotin” (counts retrieved 2026-10-31). 1,545 of them (10.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 6,644 records.

Reviews account for 612 records (4.0%) and meta-analyses for 8. Randomized controlled trials number 43 (0.3%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 6,644 records; 2000-2009: 3,847 records; 2010-2019: 3,455 records; 2020 onward: 1,545 records6,644through 19993,8472000-20093,4552010-20191,5452020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19996,644
2000-20093,847
2010-20193,455
2020 onward1,545
Share of records by publication typeReviews: 4.0 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.3 percentReviews4.0% (612)Meta-analyses0.1% (8)Randomized controlled trials0.3% (43)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 15,491 PubMed records
TypeRecordsShare
Reviews6124.0%
Meta-analyses80.1%
Randomized controlled trials430.3%

Method: PubMed query "Biotin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Single particle cryo-EM reconstruction of 52 kDa streptavidin at 3.2 Angstrom resolution
Fan X, Wang J, Zhang X, Yang Z, Zhang JC, Zhao L, et al.
2019Research article
Design not recorded in structured metadata
139cc by
PMID 31160591 · DOI · PMC6546690
Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain
Rayaprolu S, Bitarafan S, Santiago JV, Betarbet R, Sunna S, Cheng L, et al.
2022Research article
Design not recorded in structured metadata
122cc by
PMID 35614064 · DOI · PMC9132937
PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial
Reininghaus EZ, Platzer M, Kohlhammer-Dohr A, Hamm C, Mörkl S, Bengesser SA, et al.
2020Randomized controlled trial
Design not recorded in structured metadata
108cc by
PMID 33171595 · DOI · PMC7695208
The Electric Field in Solid State Nanopores Causes Dissociation of Strong Biomolecular Interactions
Liu W, Andersson J, Järlebark J, Shaji A, Sha J, Dahlin A
2025Research article
Design not recorded in structured metadata
7cc by
PMID 40389804 · DOI · PMC12186603

Single particle cryo-EM reconstruction of 52 kDa streptavidin at 3.2 Angstrom resolution [1]

Research article Fan X, Wang J, Zhang X, Yang Z, Zhang JC, Zhao L, et al. · · 2019 · cited 139 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The fast development of single-particle cryogenic electron microscopy (cryo-EM) has made it more feasible to obtain the 3D structure of well-behaved macromolecules with a molecular weight higher than 300 kDa at ~3 Å resolution.
Closing excerpt
We demonstrate that the method has the potential to determine the structures of molecules as small as 39 kDa.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (118 words)

The fast development of single-particle cryogenic electron microscopy (cryo-EM) has made it more feasible to obtain the 3D structure of well-behaved macromolecules with a molecular weight higher than 300 kDa at ~3 Å resolution. However, it remains a challenge to obtain the high-resolution structures of molecules smaller than 200 kDa using single-particle cryo-EM. In this work, we apply the Cs-corrector-VPP-coupled cryo-EM to study the 52 kDa streptavidin (SA) protein supported on a thin layer of graphene and embedded in vitreous ice. We are able to solve both the apo-SA and biotin-bound SA structures at near-atomic resolution using single-particle cryo-EM. We demonstrate that the method has the potential to determine the structures of molecules as small as 39 kDa.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31160591 · DOI · PMC6546690

Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain [2]

Research article Rayaprolu S, Bitarafan S, Santiago JV, Betarbet R, Sunna S, Cheng L, et al. · · 2022 · cited 122 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Proteomic profiling of brain cell types using isolation-based strategies pose limitations in resolving cellular phenotypes representative of their native state.
Closing excerpt
This approach will facilitate the characterization of cell-type specific proteomes in a diverse number of tissues under both physiological and pathological states.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (151 words)

Proteomic profiling of brain cell types using isolation-based strategies pose limitations in resolving cellular phenotypes representative of their native state. We describe a mouse line for cell type-specific expression of biotin ligase TurboID, for in vivo biotinylation of proteins. Using adenoviral and transgenic approaches to label neurons, we show robust protein biotinylation in neuronal soma and axons throughout the brain, allowing quantitation of over 2000 neuron-derived proteins spanning synaptic proteins, transporters, ion channels and disease-relevant druggable targets. Next, we contrast Camk2a-neuron and Aldh1l1-astrocyte proteomes and identify brain region-specific proteomic differences within both cell types, some of which might potentially underlie the selective vulnerability to neurological diseases. Leveraging the cellular specificity of proteomic labeling, we apply an antibody-based approach to uncover differences in neuron and astrocyte-derived signaling phospho-proteins and cytokines. This approach will facilitate the characterization of cell-type specific proteomes in a diverse number of tissues under both physiological and pathological states.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35614064 · DOI · PMC9132937

PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial [3]

Randomized controlled trial Reininghaus EZ, Platzer M, Kohlhammer-Dohr A, Hamm C, Mörkl S, Bengesser SA, et al. · · 2020 · cited 108 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Gut microbiota are suspected to affect brain functions and behavior as well as lowering inflammation status.
Closing excerpt
However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (240 words)

Gut microbiota are suspected to affect brain functions and behavior as well as lowering inflammation status. Therefore, an effect on depression has already been suggested by recent research. The aim of this randomized double-blind controlled trial was to evaluate the effect of probiotic treatment in depressed individuals. Within inpatient care, 82 currently depressed individuals were randomly assigned to either receive a multistrain probiotic plus biotin treatment or biotin plus placebo for 28 days. Clinical symptoms as well as gut microbiome were analyzed at the begin of the study, after one and after four weeks. After 16S rRNA analysis, microbiome samples were bioinformatically explored using QIIME, SPSS, R and Piphillin. Both groups improved significantly regarding psychiatric symptoms. Ruminococcus gauvreauii and Coprococcus 3 were more abundant and β-diversity was higher in the probiotics group after 28 days. KEGG-analysis showed elevated inflammation-regulatory and metabolic pathways in the intervention group. The elevated abundance of potentially beneficial bacteria after probiotic treatment allows speculations on the functionality of probiotic treatment in depressed individuals. Furthermore, the finding of upregulated vitamin B6 and B7 synthesis underlines the connection between the quality of diet, gut microbiota and mental health through the regulation of metabolic functions, anti-inflammatory and anti-apoptotic properties. Concluding, four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment. However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33171595 · DOI · PMC7695208

The Electric Field in Solid State Nanopores Causes Dissociation of Strong Biomolecular Interactions [4]

Research article Liu W, Andersson J, Järlebark J, Shaji A, Sha J, Dahlin A · · 2025 · cited 7 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Electrical sensing with nanopores has become a widely used bioanalytical tool.
Closing excerpt
These results show that nanopore sensors can give very inaccurate results when used for affinity-based detection or biomolecular interaction analysis and that the pore environment should be regarded as potentially invasive for the molecules inside.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (140 words)

Electrical sensing with nanopores has become a widely used bioanalytical tool. However, it remains unclear if and how the extremely strong electric field generated inside the pores influences biomolecular interactions. Here we show that the field disrupts the strongest known protein-ligand interaction in biology, namely biotin-avidin bonds. Remarkably, the lifetime of the interaction is decreased by at least 4 orders of magnitude. At hundreds of mV, avidin (from egg-white) starts dissociating from biotin-functionalized nanopores over a time scale of minutes even at the maximum bond valency of four. Streptavidin-coated nanoparticles, which form many more bonds, remain bound but exhibit surface mobility due to the field. These results show that nanopore sensors can give very inaccurate results when used for affinity-based detection or biomolecular interaction analysis and that the pore environment should be regarded as potentially invasive for the molecules inside.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40389804 · DOI · PMC12186603

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Structure and function of biotin-dependent carboxylases [5]
    Tong L · Cell Mol Life Sci · 2013 · cited 331 times (Europe PMC)
  • Research article Streptavidin-biotin technology: improvements and innovations in chemical and biological applications [6]
    Dundas CM, Demonte D, Park S · Appl Microbiol Biotechnol · 2013 · cited 312 times (Europe PMC)
  • Research article The mechanism of biotin-dependent enzymes [7]
    Knowles JR · Annu Rev Biochem · 1989 · cited 277 times (Europe PMC)
  • Research article Pathway tracing using biotinylated dextran amines [8]
    Reiner A, Veenman CL, Medina L, Jiao Y, Del Mar N, Honig MG · J Neurosci Methods · 2000 · cited 274 times (Europe PMC)
  • Research article Introduction to avidin-biotin technology [9]
    Wilchek M, Bayer EA · Methods Enzymol · 1990 · cited 271 times (Europe PMC)
  • Research article Mechanisms and regulation of biosynthesis of saturated fatty acids [10]
    Volpe JJ, Vagelos PR · Physiol Rev · 1976 · cited 231 times (Europe PMC)

References

  1. Fan X, Wang J, Zhang X, Yang Z, Zhang JC, Zhao L, et al.. Single particle cryo-EM reconstruction of 52 kDa streptavidin at 3.2 Angstrom resolution. . 2019. PMID 31160591 · DOI · PMC6546690
  2. Rayaprolu S, Bitarafan S, Santiago JV, Betarbet R, Sunna S, Cheng L, et al.. Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain. . 2022. PMID 35614064 · DOI · PMC9132937
  3. Reininghaus EZ, Platzer M, Kohlhammer-Dohr A, Hamm C, Mörkl S, Bengesser SA, et al.. PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial. . 2020. PMID 33171595 · DOI · PMC7695208
  4. Liu W, Andersson J, Järlebark J, Shaji A, Sha J, Dahlin A. The Electric Field in Solid State Nanopores Causes Dissociation of Strong Biomolecular Interactions. . 2025. PMID 40389804 · DOI · PMC12186603
  5. Tong L. Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci. 2013. PMID 22869039 · DOI · PMC3508090
  6. Dundas CM, Demonte D, Park S. Streptavidin-biotin technology: improvements and innovations in chemical and biological applications. Appl Microbiol Biotechnol. 2013. PMID 24057405 · DOI
  7. Knowles JR. The mechanism of biotin-dependent enzymes. Annu Rev Biochem. 1989. PMID 2673009 · DOI
  8. Reiner A, Veenman CL, Medina L, Jiao Y, Del Mar N, Honig MG. Pathway tracing using biotinylated dextran amines. J Neurosci Methods. 2000. PMID 11074093 · DOI
  9. Wilchek M, Bayer EA. Introduction to avidin-biotin technology. Methods Enzymol. 1990. PMID 2201884 · DOI
  10. Volpe JJ, Vagelos PR. Mechanisms and regulation of biosynthesis of saturated fatty acids. Physiol Rev. 1976. PMID 6981 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Vitamin B 12Drugs and Chemicals
  • AcetazolamideDrugs and Chemicals
  • AminopyrineDrugs and Chemicals
  • AnastrozoleDrugs and Chemicals
  • AntipyrineDrugs and Chemicals
  • AtorvastatinDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

15,491
PubMed records on this heading
10%
published since 2020
612
review articles
43
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Vitamin B 12Drugs and Chemicals
  • AcetazolamideDrugs and Chemicals
  • AminopyrineDrugs and Chemicals
  • AnastrozoleDrugs and Chemicals
  • AntipyrineDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support